Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Alliance for Clinical Trials in Oncology
NYU Langone Health
Children's Oncology Group
National Cancer Institute (NCI)
Barbara Ann Karmanos Cancer Institute